New Study Results Immiment for Implantable Heartpump

Published date : 21 August 2013
Article date : 20 August 2013

Mass Device reports that medical device manufacturer HeartWare is progressing a premarket approval application with the FDA. The company anticipates that new study results will address concerns about the rate of neurological events associated with with its Endurance implantable heart pump.

They say that researchers noted an unexpectedly high rate of ischemic and hemorrhagic strokes in HeartWare patients (6.7% and 5.1% respectively) in comparison to a control pump (4.3% and 0%, respectively). Apparently, Heartware subsequently targeted blood pressure management as a potential route for stemming further adverse events.

The manufacturer is working towards presenting the latest clinical findings at the 2014 American Heart Association or the subsequent meeting of the American College of Cardiology. 

Source: Mass Device 

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.